Gilead Sciences (GILD) closed a strong second quarter, and Wall Street noticed.
The drugmaker beat sales expectations across its biggest franchises, raised its full-year outlook, and gave analysts fresh reasons to stay bullish heading into the back half of 2026
Bank of America was one of them. The bank reiterated its Buy rating and kept its $162 price target after the report, well above where the stock trades today. One prevention number in particular caught BofA’s attention, and it speaks directly to whether Gilead’s next growth engine can last.
Why Bank of America is standing by Gilead stock after earnings Gilead reported second-quarter product sales of $7.6 billion, ahead of Wall Street estimates, driven by strength across its HIV, liver, and oncology franchises. Bank of America Global Research kept its Buy rating and $162 price target after the print, according to a research report shared with TheStreet. With the stock near $135, that target implies meaningful room to climb.